SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers

Inclusion Criteria:

- Histologically confirmed advanced malignancy defined as any of the following tumors
for which no further standard or curative therapy exists or is considered appropriate
by the Investigator:

- Epithelial ovarian cancer, including fallopian tube cancer or primary peritoneal
cancer, of high-grade serous histology, with platinum refractory or resistant
disease after prior treatment with at least one platinum-based chemotherapeutic
regimen. In Part B (dose expansion), subjects may have received no more than 3
lines of systemic cytotoxic chemotherapy.

- Note, the line of therapy limit does not apply to the biopsy substudy
cohorts.

- Metastatic or advanced endometrial carcinoma previously treated with at least 1
platinum-based chemotherapeutic regimen.

- Eastern Cooperative Oncology Group (ECOG) 0-1.

- Adequate hematologic, hepatic, and renal function.

Exclusion Criteria:

- Participants with prior exposure to a pyrrolobenzodiazepine or indolinobenzodiazepine
based drug.